Bellevue Group AG Sells 23,367 Shares of Inspire Medical Systems, Inc. $INSP

Bellevue Group AG trimmed its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 23.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 75,660 shares of the company’s stock after selling 23,367 shares during the period. Bellevue Group AG owned 0.26% of Inspire Medical Systems worth $9,818,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Quarry LP raised its stake in Inspire Medical Systems by 2,127.3% in the 1st quarter. Quarry LP now owns 245 shares of the company’s stock valued at $39,000 after acquiring an additional 234 shares during the period. Banque Transatlantique SA acquired a new position in shares of Inspire Medical Systems in the first quarter valued at $46,000. Smartleaf Asset Management LLC raised its position in shares of Inspire Medical Systems by 27.2% in the first quarter. Smartleaf Asset Management LLC now owns 454 shares of the company’s stock valued at $71,000 after purchasing an additional 97 shares during the period. Daiwa Securities Group Inc. lifted its stake in shares of Inspire Medical Systems by 38.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after buying an additional 130 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in shares of Inspire Medical Systems by 14.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 603 shares of the company’s stock worth $78,000 after buying an additional 77 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the sale, the director directly owned 26,046 shares in the company, valued at $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.10% of the stock is owned by insiders.

Inspire Medical Systems Price Performance

Inspire Medical Systems stock opened at $130.52 on Friday. The firm has a market cap of $3.79 billion, a PE ratio of 88.79, a price-to-earnings-growth ratio of 15.83 and a beta of 0.70. The stock’s fifty day moving average price is $96.44 and its two-hundred day moving average price is $104.75. Inspire Medical Systems, Inc. has a one year low of $70.77 and a one year high of $216.01.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.53. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The company had revenue of $224.50 million for the quarter, compared to analyst estimates of $220.39 million. During the same period in the prior year, the firm posted $0.60 EPS. Inspire Medical Systems’s quarterly revenue was up 10.5% on a year-over-year basis. Sell-side analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on INSP shares. Wolfe Research raised shares of Inspire Medical Systems from a “peer perform” rating to an “outperform” rating and set a $180.00 price target on the stock in a report on Tuesday, November 25th. Evercore ISI lowered their target price on Inspire Medical Systems from $150.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Oppenheimer raised Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $175.00 price target for the company in a report on Monday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Inspire Medical Systems in a report on Wednesday. Finally, KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, November 4th. Ten analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Inspire Medical Systems currently has a consensus rating of “Moderate Buy” and an average target price of $132.65.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.